
Substitution therapy | Virtual Summit 2020
Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor
Year: 2022
Language: Italian
Author(s): World Federation of Hemophilia
Format: Document
This document is an introductory guide to the World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR). It answers basic questions about the registry, its purpose, and what participants can expect. The guide is designed to help those who receive gene therapy for hemophilia and their care teams to decide if they should participate in the registry.
Please reach out to WFH with questions regarding participation in the registry at [email protected].
This guide is also available in: English, French, Spanish
DOCUMENTS AND PDFS
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor

With regulatory approval of the first gene therapy product expected, there is an urgent need for a mechanism to collect

We are still learning about gene therapy. Each patient experience is different, and gene therapy is not for everyone –

The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals.

Listen to this 2-hour webinar presented on July 27, 2021 to learn about global topics related to bleeding disorders. The

In this session from the WFH 2020 Virtual Summit, Steve Pipe and Luigi Naldini explore the promise of gene therapy